They must begin issuing payment by September 30.
Private insurance companies are expecting to pay out a record of at least $1.3 billion in rebates to consumers this fall across all markets, surpassing the previous record high of $1.1 billion in 2012, according to a new study by the Henry J. Kaiser Family Foundation (KFF).
The amount varies by market, with insurers reporting at least $743 million in the individual market, $250 million in the small group market, and $284 million in the large group market, according to analysis of data reported by insurers to CMS.
The Medical Loss Ratio (or MLR) requirement of the ACA limits the portion of premium dollars health insurers may use for administration, marketing, and profits. Under the ACA, health insurers must publicly report the portion of premium dollars spent on healthcare and quality improvement and other activities in each state in which they operate. The MLR provision requires insurance companies that cover individuals and small businesses to spend at least 80% of their premium income on healthcare claims and quality improvement, leaving the remaining 20% for administration, marketing, and profit.
Rebates are the result of insurance companies not meeting the ACA’s medical loss ratio threshold. By law, insurers have until September 30 to begin issuing rebates.
Related: Drug Price Reform Takes Off in 2019
Rebates will vary by state. The states with the largest expected rebates in total include Virginia ($149.6 million), Pennsylvania ($130 million), and Florida ($107.4 million). In about 13 states, insurers are not expecting to pay any rebates at all.
In the individual market alone, insurers will pay out the highest rebates in Virginia ($111.3 million), followed by Arizona ($92.3 million), and Texas ($80.4 million). On a per subscriber basis, insurers will pay the highest rebates in Pennsylvania ($990 per subscriber), Virginia ($770 per subscriber), and Minnesota ($670). Virginia ranks high largely because one insurer, Sentara (also known as Optima), had the highest individual premiums in the country in 2018 and now owes especially large rebates
Rebates also will vary by insurer. Other insurers issuing large rebates across the individual market include Centene (at least $216.9 million), HCSC ($78.5 million), Cigna ($55.9 million), and Highmark ($50.8 million). These insurers tend to have high enrollment and participate in a number of states.
Payers may issue the rebates in the form of a check to consumers or as a credit applied to the premiums consumers must pay. For people with employer coverage, the rebate may be shared between the employer and employee.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More